Skip to Content

Jentadueto Approval History

  • FDA approved: Yes (First approved January 30th, 2012)
  • Brand name: Jentadueto
  • Generic name: linagliptin and metformin hydrochloride
  • Dosage form: Tablets
  • Company: Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly
  • Treatment for: Diabetes, Type 2

Jentadueto (linagliptin and metformin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Development History and FDA Approval Process for Jentadueto

May 31, 2016Approval FDA Approves Once-Daily Jentadueto XR (linagliptin and metformin hydrochloride extended-release) for Type 2 Diabetes
Feb  1, 2012Approval FDA Approves Jentadueto (linagliptin/metformin hydrochloride) for the Treatment of Adult Patients with Type 2 Diabetes

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.